SPRB.US Spruce Biosciences, Inc. Common Stock

Healthcare Biotechnology USA Stocks
40.49 USD
Close of Nov 18, 2026
38.06 115.00
Market cap
USD 116M
P/E
-
P/B
1.85x
ROE
-105.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SPRB.US undervalued?

Graham number

The Graham number of Spruce Biosciences, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Spruce Biosciences, Inc. Common Stock fundamental analysis

No fundamental analysis for Spruce Biosciences, Inc. Common Stock yet.

Spruce Biosciences, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Spruce Biosciences, Inc. Common Stock

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and so…

Full company profile